Status:
TERMINATED
Treatment of Aggressive Localized Lymphoma
Lead Sponsor:
French Innovative Leukemia Organisation
Conditions:
B Cell Lymphoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Prospective and multicentric Phase III study, evaluation of the interest of the radiotherapy after 4 or 6 cycles of CHOP 14 R regimen of chemotherapy , patients with agressive and localized B lymphoma...
Detailed Description
CHOP 14 R regimen of chemotherapy is a good standard in the treatment of agressive and localized B lymphoma. Interest of the radiotheraphy
Eligibility Criteria
Inclusion
- Age \> 18 and \< 75 years
- Diffuse B large cell lymphoma , CD 20+
- Ann Arbor stage I or II withe a bulk \<7 cm
- stage i ou II confirmed by the PET-scan
- No previously treated
- HIV negative
- Signed Informed consent
Exclusion
- Age\< 18 and \> 75 years
- other type of lymphoma
- CD20 negative
- Ann Arbor stage \>II or bulk \> 7 cm
- HIV positive
- Contraindication to Rituximab use according to Sm PC
- Containdication to antracyclin
- cancer or history of cancer , excepted in situ cancer of the cervix or skin epithelioma
- Refusal of sign the informed consent
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
334 Patients enrolled
Trial Details
Trial ID
NCT00841945
Start Date
April 1 2005
End Date
February 1 2017
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Regional university hospital
Rennes, France, 35033